KURA Live signaler | Maksimer profitt med Getagraph.com

KJøP 105283 min ago

@ $19.65

Utstedt: 14 feb 2024 @ 21:45

Avkastning: 0.00%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: -2.04 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	543 365
Gjennomsnittsvolum	1.14M
Markedsverdi	1.50B
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $-0.560 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.45
ATR14	$0.0160 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Doyle Thomas James	Sell	594	Common Stock
2024-01-29	Doyle Thomas James	Sell	761	Common Stock
2024-01-29	Doyle Thomas James	Sell	963	Common Stock
2024-01-29	Bair Teresa Brophy	Sell	2 053	Common Stock
2024-01-29	Ford Kathleen	Sell	1 496	Common Stock

INSIDER POWER
42.08
Last 95 transactions
Buy: 6 371 376 \| Sell: 2 723 562

Volum Korrelasjon

Lang: 0.46 (neutral)

Kort: -0.82 (strong negative)

Signal:(62.055) Neutral

Kura Oncology Inc Korrelasjon

10 Mest positive korrelasjoner
RMRM	0.943
GAINL	0.888
LQDT	0.876
TRVN	0.857
SLNH	0.85
QTEK	0.834
SWVL	0.825
HYMC	0.824
VYNT	0.817
LITM	0.808

10 Mest negative korrelasjoner
FANH	-0.844

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kura Oncology Inc Korrelasjon - Valuta/Råvare

0.62
( weak )

0.55
( weak )

0.00
( neutral )

-0.02
( neutral )

-0.12
( neutral )

0.46
( neutral )

Kura Oncology Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2023
Omsetning:	$0
Bruttogevinst:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2022
Omsetning:	$0
Bruttogevinst:	$-759 000 (0.00 %)
EPS:	$-2.03

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.970

Financial Reports:

No articles found.

Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.